Back to Journals » Therapeutics and Clinical Risk Management » Volume 14

The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL

Authors Forsberg MH, Das A, Saha K, Capitini CM

Received 1 June 2018

Accepted for publication 9 July 2018

Published 3 September 2018 Volume 2018:14 Pages 1573—1584


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Garry Walsh

Video abstract presented by Matthew H Forsberg.

Views: 1053

Matthew H Forsberg,1 Amritava Das,2,3 Krishanu Saha,2,4,5 Christian M Capitini,1,6

1Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; 2Wisconsin Institute for Discovery, University of Wisconsin, Madison, WI, USA; 3Morgridge Institute for Research, University of Wisconsin, Madison, WI, USA; 4Department of Medical History & Bioethics, University of Wisconsin, Madison, WI, USA; 5Department of Biomedical Engineering, University of Wisconsin, Madison, WI, USA; 6Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI, USA

Abstract: Recent advancements in immuno-oncology have resulted in the generation of novel therapies such as chimeric antigen receptor (CAR) T cells, which have revolutionized the treatment of pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia. The journey of tisagenlecleucel (formerly CTL019) from early preclinical success to the US Food and Drug Administration approval is summarized in this review. Strategies that are currently being investigated to improve the efficacy and safety profile of CAR T-cells are also explored, as well as the factors contributing to the present state of patient access to CAR T therapy.

Keywords: CAR T-cells, tisagenlecleucel, acute lymphoblastic leukemia, CD19, cancer immunotherapy, chimeric antigen receptor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]